See package insert. How to take and store Felbamate? Follow your doctor’s directions. Call if you have any questions. Usually, your doctor will tell you to start by. Felbatol is the brand name used in the United States for felbamate. Read the black box warning in the Package Insert to your patient and obtain any necessary . Felbamate, also known as Felbatol, has been approved by the Food and Drug about all potential risks before using this drug and read the package insert.
| Author: | Maugar Balar |
| Country: | Myanmar |
| Language: | English (Spanish) |
| Genre: | History |
| Published (Last): | 21 December 2012 |
| Pages: | 199 |
| PDF File Size: | 20.88 Mb |
| ePub File Size: | 7.29 Mb |
| ISBN: | 638-5-19998-372-9 |
| Downloads: | 59453 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Gror |
Patients receiving anticonvulsants had approximately twice the risk of suicidal behavior pcakage ideation 0. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: We do not record any personal information entered above. Felbamate is a CYP3A4 inducer, which may result in decreased bedaquiline systemic exposure AUC and possibly reduced therapeutic effect.
Felbamate is contraindicated in patients with a history of any hematological disease e. Therefore, it is recommended that felbamate only be used in patients with severe epilepsy for which the benefits of the drug outweigh the risks of hepatic failure and other toxicities.
Higher lidocaine doses may be required; titrate to effect. Prior to this request, preliminary evidence had suggested a possible link between anticonvulsant use and suicidality.
Moderate The plasma concentration and efficacy of frlbamate may be reduced packagee administered concurrently with felbamate. Use clopidogrel and felbamate together with caution and monitor for reduced efficacy of clopidogrel.
Felbatol (felbamate) dose, indications, adverse effects, interactions from
Pacckage effect of food on GI absorption from the oral suspension has not been evaluated. Minor Bone marrow suppression is associated with guanidine therapy.
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide: Affected cytochrome P isoenzymes: Coadministration is expected to decrease the plasma concentration of dapsone and increase the formation of dapsone hydroxylamine a metabolite associated with hemolysis. Major Coadministration of felbamate with atazanavir is not recommended.
Major Concurrent administration of felbamate with ritonavir may result in decreased plasma concentrations of ritonavir.
Theoretically, CYP2C19 inhibitors, such as felbamate, may result in elevated voriconazole serum concentrations when coadministered. However, this is considered to be a class effect. The drug is not recommended for children under the age of 2 years or in infants. The plasma half-life of felbamate is 13—23 hours and is not changed after multiple doses. Concomitant use may decrease the plasma concentration and effectiveness of ulipristal.
Data were analyzed from drugs with adequately designed clinical trials including carbamazepine, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, valproate, and zonisamide.
Monitor for antiviral efficacy if these drugs are administered together.
PDR Search
Pzckage Use caution when administering velpatasvir with packagf. Serum concentrations of other anticonvulsants should be obtained and dosage adjustments made as necessary. The use of felbamate is associated with a marked increase in the incidence of aplastic anemia pancytopenia in the presence of a bone marrow largely depleted of hematologic precursor cells. These channels are regulated by the amino acid glycine. The binding of glycine to the NMDA receptor causes an increase in the frequency of NMDA receptor-mediated channel opening, which is important in the initiation and propagation of seizures.
Major Avoid concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis, such as felbamate; however, if this is not possible, closely monitor the absolute neutrophil count and interrupt deferiprone therapy if neutropenia develops. Theoretically, CY2C19 inhibitors, such as felbamate, could increase carisoprodol plasma levels, with potential for enhanced CNS depressant effects. Moderate Coadministration of mefloquine and anticonvulsants may result in lower than expected anticonvulsant concentrations and loss of seizure control.
An alternate or additional form of contraception should be used during concomitant treatment. Induction of CYP3A4 by felbamate may significantly reduce the plasma concentrations of simeprevir, resulting in treatment failure. Moderate Concomitant administration of alprazolam with CNS-depressant drugs, including anticonvulsants, can potentiate the CNS effects of either agent. Minor Coadministration of rivaroxaban and felbamate may result in decreased rivaroxaban exposure and may decrease the efficacy of rivaroxaban.
Adverse effects, such as sedation, lethargy, ataxia, or insomnia may be potentiated.